

Anti-CD22 ⁹⁰Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma

Thomas E. Witzig,¹ Michael B. Tomblyn,² Jamal G. Misleh,³ Ebenezer A. Kio,⁴ Robert M. Sharkey,⁵ William A. Wegener,⁵ and David M. Goldenberg^{5,6}

¹Mayo Clinic, Rochester, MN; ²H. Lee Moffitt Cancer Center, Tampa, FL; ³Helen F Graham Cancer Center, Newark, DE; ⁴Indiana University Health Center for Cancer Care, Goshen, IN; and ⁵Immunomedics, Morris Plains, NJ; ⁶Garden State Cancer Center, Center for Molecular Medicine and Immunology, Morris Plains, NJ, USA

©2014 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2014.112110

Manuscript received on June 11, 2014. Manuscript accepted on August 14, 2014.

Correspondence: dmg.gscancer@att.net

Online Supplementary Material

Anti-CD22 ⁹⁰Y-Epratuzumab Tetraxetan Combined with Anti-CD20 Veltuzumab: A Phase I Study in Patients with Relapsed/Refractory, Aggressive Non-Hodgkin Lymphoma (Witzig et al.)

Table S-1. Incidence of most frequent adverse events (≥ 10%)				
	All Events		Events at Least Possibly Due to Study Drug	
	All Grades	Grade ≥3	All Grades	Grade ≥3
	N (%)	N (%)	N (%)	N (%)
Patients with at least one episode of:				
Any event	18 (100%)	12 (67%)	15 (83%)	9 (50%)
Fatigue	13 (72%)	1 (6%)	8 (44%)	0 (0%)
Nausea	8 (44%)	0 (0%)	4 (22%)	0 (0%)
Anorexia	8 (44%)	0 (0%)	3 (17%)	0 (0%)
Thrombocytopenia	8 (44%)	7 (39%)	8 (44%)	7 (39%)
Anemia	5 (28%)	1 (6%)	4 (22%)	1 (6%)
Neutropenia	4 (22%)	4 (22%)	4 (22%)	4 (22%)
Cough	4 (22%)	0 (0%)	1 (6%)	0 (0%)
Diarrhea	4 (22%)	0 (0%)	1 (6%)	0 (0%)
Abdominal pain	3 (17%)	0 (0%)	1 (6%)	0 (0%)
Leukopenia	3 (17%)	2 (11%)	3 (17%)	2 (11%)
Extremity/back pain	3 (17%)	1 (6%)	0 (0%)	0 (0%)
Headache	3 (17%)	0 (0%)	1 (6%)	0 (0%)
Chills	3 (17%)	0 (0%)	0 (0%)	0 (0%)
Dyspnea	3 (17%)	0 (0%)	1 (6%)	0 (0%)
Pruritus	3 (17%)	0 (0%)	1 (6%)	0 (0%)
Rash	3 (17%)	0 (0%)	0 (0%)	0 (0%)
Vomiting	3 (17%)	0 (0%)	1 (6%)	0 (0%)

Table S-2. Radiation Dosimetry						
Mean (Range) Organ Total Radiation Doses (cGy)						
⁹⁰Y Dose Level (mCi/m²)	N	Kidneys	Liver	Lungs	Red Marrow	Whole Body
15	3	746 (532-1,099)	700 (580-907)	680 (456-1,003)	199 (113-261)	162 (119-189)
12	3	448 (313-651)	570 (392-750)	410 (362-494)	155 (85-208)	97 (72-116)
9	6	544 (402-675)	451 (247-617)	410 (322-463)	131 (110-177)	88 (78-98)
6	6	304 (194-386)	353 (277-434)	263 (197-311)	81 (66-105)	53 (44-64)
Mean ± SD Organ Radiation Dose Per mCi ⁹⁰Y Administered (cGy/mCi)						
Overall	N	Kidneys	Liver	Lungs	Red Marrow	Whole Body
	18	13.0 ± 2.9	13.3 ± 3.5	11.0 ± 2.1	3.7 ± 1.2	2.4 ± 0.3

Table S-3. Serum Chemistry (Mean ± Standard Deviation)				
	Baseline	Day 22	Week 4	Week 12
Creatinine, mg/dL	0.9 ± 0.2	0.9 ± 0.1	0.9 ± 0.2	0.9 ± 0.2
SGOT (AST), U/L	24.9 ± 6.8	22.9 ± 6.1	23.0 ± 5.1	24.6 ± 5.8
SGPT (ALT), U/L	22.9 ± 9.4	18.1 ± 6.7	19.8 ± 7.7	20.5 ± 8.4
Total bilirubin, mg/dL	0.7 ± 0.3	0.7 ± 0.2	0.6 ± 0.2	0.6 ± 0.3
Alkaline phosphatase, U/L	99.3 ± 37.3	87.4 ± 20.0	83.6 ± 21.4	90.4 ± 24.2